Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Drug maker Teva Pharmaceutical Industries Inc  and the three biggest U.S. drug distributors reached a settlement on Monday to avoid a trial over their role in the opioid addiction crisis, a source said on Monday.

Teva, three U.S. drug distributors reach opioid settlement - source

AmerisourceBergen

Cardinal Health

McKesson

Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Drug companies reach settlement as opioid trial set to begin

Four drug companies on Monday reached a settlement deal with two Ohio counties on the fight over who is responsible for the opioid epidemic that has ravaged the United States, according to a report in The Wall Street Journal.

Four drug companies reportedly reach a last-minute opioid settlement with two Ohio counties

REHOVOT, Israel and BRIDGEWATER, N.J., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it has entered into a settlement and license agreement with an affiliate of Teva Pharmaceuticals Industries Ltd. (“Teva”) to resolve pending patent litigation involving Finacea® Foam. Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice.

Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

Shares of McKesson Corp. MCK, +1.16% , Cardinal Health Inc. CAH, +0.64% , AmerisourceBergen Corp.

McKesson, Cardinal Health, Amerisource Bergen and Teva stocks all fall after settling with Ohio counties on opioid suit

Teva shares jumped higher after Gabelli upgraded the stock, saying that $15 billion in drug giveaways could have a limited EBITDA impact.

Teva Breaks Out Amid Hopes of Global Opioid Settlement

Johnson & Johnson

The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.

Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits

Teva Pharmaceuticals  is in talks to contribute over $15 billion worth of drugs as part of a settlement to resolve lawsuits alleging it helped fuel the U.S. opioid crisis, a source familiar with the matter told Reuters on Wednesday.

Teva to donate over $15 billion worth of drugs in opioid settlement: source

CVS Health

Mallinckrodt PLC

The health care industry could be forced to pay out as much as $150 billion.

5 Stocks That Could Get Crushed By Opioid Lawsuit Tidal Wave

The fast-paced marijuana industry continues to attract non-traditional players.

This Opioid Producer Just Said Yes to Cannabis

The stock market has traded hysterically every bit of news related to the opioid crisis.

Teva: Opioids For All, But Not For Mr. Market

American Airlines

Delta Air Lines

Southwest Airlines

United Continental Hlds

These stocks don't match the qualities Buffett typically looks for in an investment.

Warren Buffett's Most Baffling Stock Holdings

The world's largest manufacturer of prescription drugs has officially entered the medical marijuana industry.

Cannabis and Big Pharma Join Hands in Jerusalem

Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential.

Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal

According to information procured exclusively a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers.

Exclusive: One Of The Largest Pharma Companies In The World Just Got Into Cannabis

Apple

American Express

Kraft Heinz

Coca-Cola

So far this year, here are the winners and losers of Oracle of Omaha's favored companies.

Buffett's Best & Worst Performing Stocks Thus Far in 2019

AbbVie

Bristol-Myers

Eli Lilly

Merck

Pfizer

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Short Sellers Can’t Make Up Their Minds on Big Pharma

FedEx

Tanger Factory Outlet Centers

Recent market volatility has created some compelling buying opportunities.

Here Are the Last 3 Stocks I Bought -- and Why

Investors continued to back away from the troubled generic-drug company as lawsuits from the opioid crisis began to conclude.

Here's Why Teva Pharmaceuticals Dropped 13% in August

Bank of New York Mellon

The performance of Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) equity portfolio this year has been a mixed bag.

These Are Buffett's Worst-Performing Stocks of 2019

Shareholders of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) are searching for any reasons to be optimistic that the battered, bruised and beaten-down generic drugmaker can emerge from the depths of despair.

Teva Hopes to Survive Onslaught of Challenges

Bayer AG

One of the world’s largest and oldest pharmaceutical companies buys out one of the world’s largest agriculture firms, and the stock collapses in freefall.

Bayer, Teva Show Antitrust Law May Be Unnecessary

Two of Berkshire Hathaway's nearly four dozen holdings have lost more than 40% of their value this year.

These 4 Stocks Have Cost Warren Buffett More Than $6 Billion in 2019

Allergan

Endo International

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

Will Opioid Litigation Take its Toll on Pharma Companies?

Teva has faced a tough couple of years, to put it mildly.

News for Teva Pharmaceutical Stock (TEVA)